Venetoclax Combos Improve Progression-Free Survival in CLL
Venetoclax/obinutuzumab as well as a triple combo with ibrutinib demonstrated better PFS in fit patients with CLL vs chemo, but higher rates of serious adverse events with ibrutinib remain a concern.
Barbara Eichhorst University Of Cologne European Hematology Association Elect Ant Medscape Medical Chronic Lymphocytic Leukemia
Source: medscape.com